German maker of medical ventilators, anesthesia machines and patient monitors, plus safety equipment like gas detectors and respiratory protection.
German maker of medical ventilators, anesthesia machines and patient monitors, plus safety equipment like gas detectors and respiratory protection.
Two arms: medical devices for operating theatres and intensive care, and safety equipment for fire services, mines and industry. A sale is followed by years of service contracts, accessories and consumables, so the installed base is a steady income source. The Draeger family controls it through voting shares; this preferred share has no vote.
In one line: A German GE Healthcare (respiratory) combined with an MSA Safety.
Moat: narrow (brand, regulatory licence, installed base). Trusted safety-critical medical and safety-equipment brand with regulatory approvals, but competes with larger med-tech/safety players.
Headquarters: Luebeck, Germany · Founded: 1889 · Employees: 16,687
Size Draegerwerk AG & Co. KGaA (DRW8.DE) is a Germany Health Care company (Medical Specialties) with a market value of $2.13B, the 103rd largest of 198 Germany companies the cockpit tracks. Shares closed at €89.40 on 18 Nov 2026.
Performance Over six months the shares gained 24.9%, against +1.1% for the median peer and -0.9% for the Germany market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 5.1% over the last twelve months (peer median +7.9%); the operating margin is 7.4% (peer median 15.2%).
Valuation It trades at 10.2× forward earnings against a peer median of 24.1× (2nd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.1 points above its cost of capital (6.1% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €3.59B | €3.48B | €3.37B | €3.37B | €3.05B |
| Revenue growth | — | +3% | 0% | +11% | — |
| Gross profit | €1.67B | €1.52B | €1.43B | €1.40B | €1.17B |
| EBITDA | €405M | €385M | €313M | €341M | €72.9M |
| Net income | €170M | €139M | €124M | €110M | -€64.6M |
| Free cash flow | €227M | €167M | €107M | €125M | -€224M |
| Capital expenditure | €105M | €80.7M | €63.8M | €68.2M | €86.9M |
| Total debt | €229M | €405M | €396M | €471M | €362M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Draegerwerk AG & Co. KGaA DRW8.DE | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% |
| GE HealthCare GEHC | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% |
| MSA Safety MSA | $6.84B | +5% | +8% | 22% | 18.3× | 9.4% |
| Getinge GETI-B.ST | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DRW8.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +28.1% | -0.8% | 3rd highest of 21 |
| 6-month return | +24.9% | +1.1% | 4th highest of 20 |
| Distance from 52-week high | -6.9% | -20.3% | 5th highest of 21 |
| Revenue growth (TTM) | +5.1% | +7.9% | 8th lowest of 21 |
| Operating margin | 7.4% | 15.2% | 7th lowest of 21 |
| Forward P/E | 10.2× | 24.1× | 2nd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -10.2% | 10.7% | 2nd least demanding of 14 |
| Growth delivered (Del g) | +0.4% | +10.4% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | -10.7 pp | -2.2 pp | 5th least demanding of 14 |
| ROIC minus cost of capital | +5.1 pp | -0.6 pp | 9th highest of 21 |
| EV / EBITDA | 4.7× | 17.1× | 2nd cheapest of 15 |
| Net debt / EBITDA | -0.1× | -0.7× | 8th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |